Last updated on January 2019

Phase 2 Study of TMX-049 in Subjects With Type 2 Diabetes and Albuminuria

Brief description of study

The primary objective of this study is to assess the effect of 2 dose levels of TMX-049 on urinary albumin excretion in subjects with Type 2 diabetes and albuminuria (a urinary albumin-to-creatinine ratio (UACR) 200 to 3000 mg/g and an estimated glomerular filtration rate (eGFR) 30 ml/min/1.73m2). Effects of each TMX-049 dose on UACR will be assessed in terms of ratios using log-transformed UACR at Baseline and after a 12-week period of treatment.

Clinical Study Identifier: NCT03449199

Contact Investigators or Research Sites near you

Start Over

Teijin America, Inc. Contact

Endocrine Associates of Florida
Ocoee, FL United States
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.